Compare Fox Corp Class A (FOXA) vs Novartis AG (NVS) Price & Performance

FOXA trades at $62.70, up 1.0% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $1.79 beating expectations by 24%. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. The pending $22B Roku acquisition faces extended DOJ review, creating regulatory uncertainty while CEO Lachlan Murdoch recently purchased $10.3M in shares.

FOXA presents a compelling value case with attractive valuation multiples (P/E 16.33, P/S 1.61) and strong profitability (ROE 14.29%). Analyst consensus targets $72.00 with 52% buy ratings, offering 15% upside potential. Key risks include regulatory hurdles for the Roku deal and projected 2026 margin compression. The stock's current technical weakness may provide entry opportunity for fundamental investors.

Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.

Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.